Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.51 |
| ▸ | FLT3 | P36888 | 8/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326149 | 0.88 | RET (0.57) | CHEK1CCNA2CDK2CCNA1IRAK4 | |
| SCHEMBL4330250 | 0.87 | PIM1 (0.49) | IRAK4FLT3PIM1PIM2RET | |
| SCHEMBL4331342 | 0.81 | PIM1 (0.63) | FLT3PIM1PIM2 | |
| SCHEMBL19269928 | 0.79 | IRAK4 (0.55) | IRAK4FLT3PIM1PIM2 | |
| SCHEMBL29788591 | 0.74 | IRAK4 (0.69) | IRAK4FLT3 | |
| SCHEMBL4337278 | 0.72 | PIM1 (0.49) | PIM1PIM2RET | |
| SCHEMBL11930774 | 0.70 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1 | |
| Trifluoroacetic Acid SCHEMBL29788577 | 0.69 | IRAK4 (0.65) | IRAK4FLT3 | |
| SCHEMBL30083537 | 0.69 | IRAK4 (0.59) | CHEK1CCNA2CDK2CCNA1IRAK4 | |
| SCHEMBL376249 | 0.69 | CCNT1 (0.46) | CHEK1CCNA2CDK2CCNA1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049539-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| WO-2007147647-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147647-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | DPYD, FLT1, PDXK | CHEK1 3163/4885CCNA2 2322/4885CDK2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.